menu
    • menu

    Company profile for Bionxt Solutions

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bionxt is striving to have a positive impact on global health We are creating potentially life-changing solutions through research, development and collaboration. Bionxt Solutions works with promising disrupters in the pharmaceutical industry; accelerates research and technology development; and commercializes products with an entrepreneurial approach and a commitment to efficiency, effectiveness and accessibility.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bionxt SolutionsCanada Flag
    Country
    Country
    Canada
    Address
    Address
    Suite 1500 – 1055 W Georgia Street Vancouver, BC V6E 4N7 C
    Telephone
    Telephone
    +1-780-818-6422
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bionxt.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioNxt Advances MS ODF Program Toward Human Trials
    BioNxt Advances MS ODF Program Toward Human Trials

    26 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-26/bionxt-accelerates-odf-for-multiple-sclerosis-toward-human-clinical-study-with-40-bioavailability

    PHARMIWEB
    26 Jan 2026
    Share Share
    BioNxt Announces Success in Final Cladribine ODF In Vivo Study
    BioNxt Announces Success in Final Cladribine ODF In Vivo Study

    19 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-19/bionxt-reports-successful-final-in-vivo-dosing-study-results-supporting-superior-bioavailability-of

    PHARMIWEB
    19 Jan 2026
    Share Share
    BioNxt Targets Global Pill-Swallowing Issue with Rapid-Dissolving
    BioNxt Targets Global Pill-Swallowing Issue with Rapid-Dissolving

    17 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-17/over-40-of-adults-struggle-to-swallow-pills-bionxt-targets-a-global-adherence-problem-with-rapid

    PHARMIWEB
    17 Dec 2025
    Share Share
    BioNxt Enhances Cladribine Formulation For MS Patients
    BioNxt Enhances Cladribine Formulation For MS Patients

    09 Dec 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionxt-advances-%22melt-in-your-mouth%22-cladribine-formulation-to-improv-1115793

    ACCESSWIRE
    09 Dec 2025
    Share Share
    BioNxt to Acquire 100% IP and Codevelop Sublingual Formulation
    BioNxt to Acquire 100% IP and Codevelop Sublingual Formulation

    01 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-01/bionxt-signs-letter-agreement-to-acquire-100-interest-in-ip-and-to-codevelop-a-sublingual-drug-form

    PHARMIWEB
    01 Dec 2025
    Share Share
    Bionxt Secures Eurasian Patent For Sublingual MS Therapy
    Bionxt Secures Eurasian Patent For Sublingual MS Therapy

    24 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/bionxt-secures-eurasian-patent-for-breakthrough-sublingual-ms-therapy-18336

    INDPHARMAPOST
    24 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search